Literature DB >> 3192039

Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients.

J Watanabe1, H J Wohltmann, R L Klein, J A Colwell, M F Lopes-Virella.   

Abstract

Low-density lipoprotein (LDL) is known to enhance platelet sensitivity to some aggregating agents. In this study, we observed that LDL isolated from patients with insulin-dependent diabetes mellitus (IDDM) enhanced thrombin-induced platelet aggregation to a greater extent than LDL isolated from matched controls (P less than .01). Thromboxane B2 production during aggregation was also significantly more enhanced by LDL isolated from IDDM than by control LDL (P less than .01). There was no difference in the lipid composition (free and esterified cholesterol, total phospholipids, and triglycerides) of LDL isolated from diabetic and control subjects. In contrast, the extent of glycosylation of LDL isolated from diabetic patients was significantly greater than that observed in LDL from normal subjects (P less than .01), and a positive correlation (r = .605, P less than .01) between the degree of LDL glycosylation and the rate of platelet aggregation was observed. LDL glycosylated in vitro enhanced thrombin-, collagen-, and adenosine 5'-diphosphate-induced platelet aggregation to a greater extent than control LDL (P less than .01). Although LDL glycosylated in vitro was taken up by platelets to a greater extent than control LDL (P less than .05), the lipid composition (free cholesterol and phospholipid) of platelets was not significantly changed. We postulate that an increased degree of glycosylation of LDL may enhance its uptake by platelets and lead to increased platelet reactivity to aggregating agents, probably by altering the structure of the platelet membrane. The enhancement of platelet aggregation by LDL may contribute to the accelerated development of atherosclerosis in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192039     DOI: 10.2337/diab.37.12.1652

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets.

Authors:  R Colas; A Sassolas; M Guichardant; C Cugnet-Anceau; M Moret; P Moulin; M Lagarde; C Calzada
Journal:  Diabetologia       Date:  2011-08-17       Impact factor: 10.122

2.  Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol.

Authors:  R Kaplan; H S Aynedjian; D Schlondorff; N Bank
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus.

Authors:  Monika Zoltowska; Edgard Delvin; Ehud Ziv; Noel Peretti; Manon Chartré; Emile Levy
Journal:  Lipids       Date:  2004-01       Impact factor: 1.880

4.  Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.

Authors:  Timothy J Lyons; Alicia J Jenkins
Journal:  Diabetes Rev (Alex)       Date:  1997

5.  Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes.

Authors:  I Ginon; C Talussot; G Ponsin; M Ciavatti
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

6.  Plasma beta-thromboglobulin and platelet factor 4 are not increased in insulin-dependent diabetic patients with microalbuminuria.

Authors:  G Gruden; P Cavallo-Perin; R Romagnoli; G Ruiu; G Pagano
Journal:  Acta Diabetol       Date:  1994-09       Impact factor: 4.280

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.